NN

Novo Nordisk AS

Organization

Heard in 9 episodes across 7 shows since Aug 2026

A Danish pharmaceutical company best known for medicines for diabetes, obesity, and other chronic diseases, including Wegovy and Ozempic.

Discussed inMarkets88%Politics13%

Episodes

9
across 7 shows

This week

0
episodes on 0 shows

Expert statements

6
6 negative

Share of the conversation

Mentions of Novo Nordisk AS per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.

0.0‰0.05‰0.1‰0.15‰0.2‰Jul 11Aug 2Aug 25Sep 16Oct 8
Show the data
DayShare (7-day)Mentions
Aug 170.03‰1
Aug 310.03‰1
Sep 110.07‰2
Sep 130.14‰2
Sep 140.15‰1
Sep 210.06‰2
Oct 70.03‰1

The full trend: rank, tone and why it is trending →

What experts have said about Novo Nordisk AS

6 statements · 6 negative

  1. Louise MoonNegativeSep 25, 2026· Stock Movers

    The Nanexa deal is unlikely to trigger Novo Nordisk’s price in the short term.

    “it's unlikely to be a short-term trigger for their price”

    Listen at 2:53

    Open the episode · UBS Rises, Novo Climbs, HelloFresh Plummets
  2. Chloe MillayNegativeSep 11, 2026· Stock Movers

    Novo Nordisk’s weight-loss pill missed expectations

    “The weight loss pill did not manage to beat expectations.”

    Listen at 1:43

    Open the episode · Novo Nordisk Drops, Puma Down, Trainline Rises
  3. Chloe MelleyNegativeAug 5, 2026· Stock Movers

    Several factors may complicate Novo Nordisk’s outlook.

    “there's going to be some, perhaps some things kind of complicating the outlook for Novo”

    Listen at 1:42

    Open the episode · Novo Nordisk Drops, Next Jumps, Infineon Falls
See all 6 statements →

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

9 episodes featuring Novo Nordisk AS, newest first

See all 9 episodes →
Novo Nordisk AS · PodLume